Search results for "Pyridazine"
showing 9 items of 69 documents
CCDC 144397: Experimental Crystal Structure Determination
2000
Related Article: J.Cano, G.De Munno, F.Lloret, M.Julve|2000|Inorg.Chem.|39|1611|doi:10.1021/ic991219l
Self-assembly of 1D- and 3D-networks through non-coordination intermolecular forces: synthesis and crystal structures of copper(I) complexes based on…
2007
Reaction of [Cu2(H3CCN)2(μ-pydz)3][PF6]2 (1) with an excess of pyridazine or phthalazine yielded the novel dinuclear complexes [Cu2(μ-pydz)3(pydz)2][PF6]2 (2) and [Cu2 (μ- pydz)(μ-phtz)2(phtz)2][PF6]2 (5), respectively. Depolymerisation of the coordination polymer 1 ∞ {[Cu(μ-pydz)2][PF6]} (3) in dichloromethane by addition of an excess of benzo[c]cinnoline afforded the dinuclear copper(I) salt [Cu2(μ-pydz)2(pydz)2(benzo[c]cinnoline)2][PF6]2 (4). Furthermore, a new route for the preparation of bis(benzonitrile)tris(μ-phthalazine)dicopper(I) bis(trifluoromethanesulfonate), [Cu2(C6H5CN)2(μ-phtz)3][CF3SO3]2 (7), was established from {[Cu(CF3SO3)]2 ・C6H5Me}, phthalazine and benzonitrile via the …
Supramolecular arrangements of novel clickable 4-substituted 3,6-bis(2′-pyridyl)pyridazine molecules
2020
Abstract The clickable reaction between the starting 3,6-bis(2′-pyridyl)-1,2,4,5-tetrazine (bptz) with a series of terminal alkynes-containing functional biomolecules [prop-2-yn-1-ol, 4-(prop-2′-yn-1′-yl)morpholine and D-galactose] by means of an inverse electron demand Diels-Alder pathway has been studied and four new 4-substituted 3,6-bis(2′-pyridyl)pyridazine derivatives (4-Rdppn) were isolated, namely 4-(hydroxymethyl)-3,6-di(pyridin-2-yl)pyridazine (1), 4-((prop-2-yn-1-yloxy)methyl)-3,6-di(pyridin-2-yl)pyridazine (2) obtained by post-etherification reaction of 1, 4-(morpholinemethyl)-(3,6-dipyridin-2-yl)pyridazine monohydrate (3) and 3,6-di(pyridin-2-yl)-4-((2,2,7,7-tetramethyltetrahyd…
CCDC 902868: Experimental Crystal Structure Determination
2013
Related Article: T.F.Mastropietro,N.Marino,D.Armentano,G.De Munno,C.Yuste,F.Lloret,M.Julve|2013|Cryst.Growth Des.|13|270|doi:10.1021/cg301415p
CCDC 902869: Experimental Crystal Structure Determination
2013
Related Article: T.F.Mastropietro,N.Marino,D.Armentano,G.De Munno,C.Yuste,F.Lloret,M.Julve|2013|Cryst.Growth Des.|13|270|doi:10.1021/cg301415p
CCDC 902871: Experimental Crystal Structure Determination
2013
Related Article: T.F.Mastropietro,N.Marino,D.Armentano,G.De Munno,C.Yuste,F.Lloret,M.Julve|2013|Cryst.Growth Des.|13|270|doi:10.1021/cg301415p
Polynuclear copper(II) complexes with μ2-1,1-azide bridges. Structural and magnetic properties
1996
Abstract Two novel, weakly antiferromagnetically coupled, tetranuclear copper(II) complexes [Cu4(PAP)2(μ2-1,1-N3)2(μ2-1,3-N3)2(μ2-CH3OH)2(N3)4 (1) (PAP = 1,4-bis-(2′-pyridylamino)phthalazine) and [Cu4(PAP3Me)2 (μ2-1,1-N3)2(μ2-1,3-N3)2(H2O)2(NO2)2]- (NO3)2 (2) (PAP3Me = 1,4-bis-(3′-methyl-2′-pyridyl)aminophthalazine) contain a unique structural with two μ2-1,1-azide intramolecular bridges, and two μ2-1,3-azide intermolecular bridges linking pairs of copper(II) centers. Four terminal azide groups complete the five-coordinate structures in 1, while two terminal waters and two nitrates complete the coordination spheres in 2. The dinuclear complexes [Cu2(PPD)(μ2-1,1-N3)(N3)2(CF3SO3)]CH3OH) (3) a…
EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils.
2005
Leukocytes contribute to the ischemia-reperfusion injury. Recent studies suggested endothelins could be important mediators for leukocyte activation in stroke. We tested if the endothelinA receptor antagonist BSF-208075 (ambrisentan) could reduce an ischemic lesion by modulation of leukocyte-endothelium interactions. Twenty-four gerbils underwent either a sham operation (n=6) or 15 min of bilateral carotid artery occlusion resulting in global cerebral ischemia. Ischemic animals received normal saline (n=6), 5 mg/kg BSF-208075 (n=6) or 30 mg/kg (n=6) administered intravenously at 10 min of reperfusion. Leukocytes rolling or adhering to endothelium were counted by intravital microscopy in par…
Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…
2020
Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…